肿瘤防治研究2026，Vol.53Issue(1)：79-85,7.DOI:10.3971/j.issn.1000-8578.2026.25.0608
维奈克拉诱导肿瘤溶解综合征病理生理分子机制及防治进展
Pathophysiological Molecular Mechanism and Progress in Prevention and Treatment of Venetoclax-Induced Tumor Lysis Syndrome
摘要
Abstract
Venetoclax is clinically used for the treatment of hematopoietic malignancies by selectively targeting and inhibiting the B cell lymphoma-2 signaling pathway.Side effects include hypocytosis,bone marrow suppression,and gastrointestinal tract reactions.In some patients,numerous tumor cells are destroyed within a short time period because of rapid apoptosis induced by venetoclax,resulting in metabolic crises,leading to acute kidney injury,electrolyte disorders,cardiac arrhythmia,and even death,causing tumor lysis syndrome(TLS).In this paper,the pathological process,molecular mechanism,clinical pathogenesis,and preventive strategy of TLS induced by venetoclax are systematically described.This research provides a theoretical basis for the rational clinical application of venetoclax.关键词
维奈克拉/Bcl-2/肿瘤溶解综合征/造血系统肿瘤Key words
Venetoclax/Bcl-2/Tumor lysis syndrome/Hematopoietic neoplasm分类
医药卫生引用本文复制引用
朱慧敏,成志勇,张朝,栗岩,杜元,李红宁..维奈克拉诱导肿瘤溶解综合征病理生理分子机制及防治进展[J].肿瘤防治研究,2026,53(1):79-85,7.基金项目
The Key Research and Development Project of Hebei Province(No.223777105D) 河北省重点研发计划(223777105D) （No.223777105D）
